News Kardigan raises $300m for cardio work, and other financings Kardigan makes its debut with a teal of ex-MyoKardia execs and a $300m war chest, with a string of other biotechs also raising funds this week.
News Bioptimus raises $41m for its GenAI model for biology AI startup Bioptimus takes its funding above $76m as it prepares for the launch of a universal foundation model for pathology later this year.
News Ouro makes debut with $120m for autoimmune disease TCEs Ouro launches today with $120m in funding and a plan to develop bispecific antibody-based T cell engagers for autoimmune diseases.
News Verdiva Bio raises $411m for obesity pipeline A new obesity startup – Verdiva Bio – has just decloaked with a whopping $411m to advance a once-weekly oral GLP-1 agonist.
News Aviceda raises $207.5m for eye drug, and other financings Our round-up of recent biotech financings includes a big round for Aviceda, with Orbis, Alebund, XyloCor, and PrimeGene also raising additional cash.
News Ottimo raises $140m for its PD-1/VEGF cancer drug Ottimo raises $140m for PD-1 and VEGF-targeting jankistomig, which the startup says is differentiated from bispecific antibodies in the class.
Patients New Boehringer US Head Brian Hilberdink talks GLP-1s, DTx an... At Reuters Pharma USA, editor-in-chief Jonah Comstock caught up with Brian Hilberdink, the new head of US human pharma at Boehringer Ingelheim.
Sales & Marketing Sponsored Health Trends 2025: Reimagining What's Possible Join the conversation, on Tuesday 28th January @ 10 am ET - 3 pm GMT - 4 pm CET, in our webinar sponsored by Syneos Health, entitled ‘Health Trends 2025: Reimagining What's Possibl